News Headlines
-
ExoXpert Announces Agreement with Neucore Bio to Evaluate Advanced Exosome Loading
4/17/2024
ExoXpert, a Contract Development and Manufacturing Organization (CDMO) specializing in exosome production and a subsidiary of Exo Biologics, today announces a strategic partnership with Neucore Bio, a next-generation, non-viral engineered delivery technology company to leverage ExoXpert’s platform for evaluation of advanced exosome loading.
-
Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership
4/16/2024
Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
-
AmplifyBio And RNAV8 Bio Announce Strategic Partnership To Support mRNA Therapeutic Developers From Sequence Design To GMP Manufacture
4/16/2024
AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.
-
BioHarvest Sciences Announces New Campus For Botanical Synthesis CDMO And Expansion Of Manufacturing Capacity
4/16/2024
BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel, and an equipment purchase agreement for 12 state of the art GMP clean rooms.
-
Medincell Enters Into Strategic Co-Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
4/16/2024
Medincell today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.
-
Curida, Small Molecules And Biologics CDMO, Secures Private Equity Investment From Signet Healthcare Partners
4/16/2024
Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position.
-
Evergreen Theragnostics Completes $26M Capital Raise To Advance Novel Radiopharmaceutical Pipeline Into The Clinic, Prepare For First Commercial Product Launch, And Expand Industry-Leading CDMO Services
4/16/2024
Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.
-
Naobios And Sumagen Sign Exclusive Partnership To Develop HIV Vaccine
4/15/2024
Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, today announces the signing of a partnership with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its phase II clinical trials. Financial terms were not disclosed.
-
Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling Of Cell Therapy Manufacturing
4/11/2024
Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM)*, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion.
-
Arvinas Enters Into A Transaction With Novartis, Including A Global License Agreement For The Development And Commercialization Of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 For The Treatment Of Prostate Cancer
4/11/2024
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer.